Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2021

Open Access 16.04.2021 | Sarcoma

Late Local Recurrence and Metastasis in Soft Tissue Sarcoma of the Extremities and Trunk Wall: Better Outcome After Treatment of Late Events Compared with Early

verfasst von: Arvid von Konow, MD, Iman Ghanei, MD, Emelie Styring, MD, PhD, Fredrik Vult von Steyern, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2021

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background

Approximately 80% of soft tissue sarcoma (STS) recurrences, local and metastatic disease, are diagnosed within the first 3 years after primary diagnosis and treatment. Recurrences, however, can present after a longer period of remission. Our goal was to identify factors that may predict the risk of late recurrence.

Methods

We identified 677 patients with STS of the extremities and trunk wall from a population-based sarcoma register. Of these, 377 patients were alive and event-free at 3 years and were included for analysis of possible risk factors for late recurrence.

Results

Fifty-five of 377 (15%) patients developed late recurrence: 23 local recurrence, 21 metastasis, and 11 both manifestations. With R0 wide surgical margin as reference, R0 marginal (hazard ratio [HR] 2.6; p = 0.02) and R1 (HR 5.0; p = 0.005) margins were risk factors for late local recurrence. Malignancy grade (HR 8.3; p = 0.04) and R0 marginal surgical margin (HR 2.3; p = 0.04) were risk factors for late metastasis. We could not find a statistically significant correlation of late recurrence with many of the generally known risk factors for local recurrence and metastasis in STS. Outcome after treatment of late recurrences was better compared with outcome after treatment of early events.

Conclusions

Late recurrences, albeit relatively rare, do occur. Outcome after treatment was good compared with outcome after early events. Long surveillance of all patients with high-grade STS, especially if R0 wide surgical margin is not achieved in the primary treatment, appear to be well justified.
Hinweise

Supplementary Information

The online version contains supplementary material available at https://​doi.​org/​10.​1245/​s10434-021-09942-8.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Soft tissue sarcomas (STS) of the extremities and trunk wall constitute a heterogenous group of malignant tumors comprising more than 50 histological subtypes.1 In mixed series of STS the 5-year disease-free survival is approximately two-thirds, with specific metastasis-free and local recurrence-free survival rates of approximately 70% and 80%, respectively.2,3 Metastatic disease, most common to the lungs, is generally associated with a poor prognosis.4
Several prognostic factors that correlate with risk for local recurrence (LR) and distant metastasis (DM) have been identified, e.g., malignancy grade, size, tumor depth, surgical margins, certain histological subtypes, and tumor characteristics.57 Staging systems from AJCC and UICC include malignancy grade, tumor size, metastatic disease, or lymph node engagement but have limited value for treatment decisions in clinical practice.5,6,810 In Sweden, the SING system is used to identify high-risk tumors. The SING system includes assessment of tumor size, vascular invasion, tumor necrosis, and growth pattern in high-grade tumors.1113
After primary treatment, follow-up surveillance includes physical examination and imaging of the chest. MRI of the primary tumor site is performed when indicated. The objective of standardized follow-up routines is to identify recurrences early in order to improve the chances of remission and long-term survival.5 ESMO and Swedish guidelines recommend follow-up for 10 years with intervals depending on malignancy grade.5,14 Approximately 80% of relapses after primary treatment occur within the first 3 years.3,5,1517 Risk factors for late recurrence are not well studied, and it has been suggested that the prognostic value of known risk factors diminish over time.1821
The purpose of this study was to investigate the STS recurrence pattern, LR and/or DM, over time and identify possible risk factors and predictors for late tumor recurrence. We have evaluated patients who were event-free and alive 3 years after primary diagnosis. Late recurrence often is defined as a recurrence diagnosed later than 5 years after the primary diagnosis and treatment.19,20,22 We have chosen 3 years as a cutoff, because we believe that it better reflects the recurrence pattern of STS (see Discussion). Prognostic factors for late LR and late DM, respectively, were evaluated with the goal to investigate whether it is possible to identify which patients would or would not benefit from a long surveillance.

Methods

We identified adult patients (>18 years) with primary STS of the extremities and trunk wall, diagnosed between 1986 and 2014 in the Southern Sweden healthcare region (1.8 million inhabitants), using the national sarcoma quality register.2,2325 Patients have prospectively been enrolled in the register, which has complete coverage compared with the national cancer register. Patients who were not surgically treated, patients with DM at diagnosis and certain histological subtypes (e.g., rhabdomyosarcoma, Ewing’s sarcoma of soft tissue, dermatofibrosarcoma protuberans, and atypical lipomatous tumor) were excluded. The register includes data on diagnosis, treatment, and outcome. In addition to register data, clinical charts were reviewed.
Patients were followed according to the Swedish and ESMO guidelines with physical examination and chest imaging. High-grade tumors were followed every third month for the first 3 years, twice per year up to 5 years, and once per year thereafter. Low-grade tumors were followed twice per year the first 5 years, and thereafter annually. Patients with first recurrence within 3 years were considered to have an early recurrence and patients with first recurrence at 3 years or later were considered to have a late recurrence. Patients with early recurrence were analyzed for reference purpose (supplementary tables).
Tumor size was determined as the largest diameter on histopathologic examination and was dichotomized at both 5 and 8 cm as these cutoffs are commonly used in other studies; 8 cm is used in the Swedish guidelines to identify high-risk tumors. Vascular invasion was defined as presence of tumor cells within any space with endothelial lining. Both vascular invasion and microscopic necrosis were classified as present or not and peripheral growth pattern as pushing or infiltrative.11,12 Tumors were classified as either superficial, if strictly located above an unengaged fascia, or deep-seated if the fascia was invaded or the tumor was located deep to the fascia. The FNCLCC histologic grading system is currently used in the clinical setting at our center. However, a large part of our series was graded using the Broders’ four-tiered system that was used before the French grading system was introduced.26 Low grade (grade 1 and 2) translates approximately to FNCLCC grade 1 and high grade (grades 3 and 4) to FNCLCC grade 2 and 3. Surgical margin was, in accordance with Swedish guidelines, classified as R0 wide if the tumor was surrounded by a 10-mm cuff of healthy fatty, muscular, or loose areolar tissue or an unengaged fascia.27,28 The margin was classified as R0 marginal if there was less than 10-mm margin or engagement of the fascia, as R1 (intralesional) if there was microscopic growth at the resection margin, or as R2 if there was macroscopic residual tumor.29,30 In cases with more than one surgical procedure performed for the primary tumor, the margin obtained at the last surgery was recorded as final margin.
The study was approved by the Lund University Ethics Committee and meet the guidelines of their responsible governmental agency.

Statistical Analysis

Statistical analysis was performed using log-rank test or Cox proportional hazard model and survival data visualized using Kaplan–Meier survival analysis. Only variables that were statistically significant in univariable analysis were included in the multivariable analysis, because the number of events would not allow all variables to be included. A global significance test was calculated using likelihood ratio test. Time to event was calculated from the date of initial diagnosis to the recurrence date. Patients were censored at the last follow-up with no evidence of disease or at death without tumor. Survival was analyzed from diagnosis date or recurrence date to death or until censored. A p value < 0.05 was considered statistically significant. Statistical analysis was performed using Stata/IC 15.1 for Mac (StataCorp LLC, TX).

Results

A total of 877 STS patients were identified of which 43 patients were excluded for not being surgically treated and 81 for having DM at the time of diagnosis. Another 61 cases were excluded due to certain histological subtypes, and 13 cases were lost to follow-up within 3 years. Two patients had insufficient data and were excluded. The remaining 677 patients were included in the study.
Of these 677 patients, 250 (37%) had recurrence within the first 3 years from initial diagnosis: 60 patients had LR, 121 had DM, and 69 had both LR and DM. Another 50 patients without recurrence died within 3 years (mean age 81 years). The event-free survival for each year is presented in Table 1 and Fig. 1a. The 5-year overall survival (OS) was 63% (95% confidence interval [CI] 59–66), and the 10-year OS was 46% (95% CI 42–50) for these 677 patients.
Table 1
Event-free survival and cumulative number of events at the end of each interval from diagnosis of soft tissue sarcoma
Interval (years)
Event-free survival (95% CI)
No. at risk at beginning of interval
Cumulative number of events
Cumulative percentage of events
Recurrence hazard rate (SE)
0 to 1
78 (75–81)
677
147
48%
0.021 (0.0017)
1 to 2
67 (63–71)
506
217
71%
0.013 (0.0015)
2 to 3
62 (58–65)
426
250
82%
0.007 (0.0012)
3 to 4
59 (55–63)
377
265
87%
0.004 (0.0009)
4 to 5
57 (53–61)
333
277
91%
0.003 (0.0009)
5 to 6
55 (51–59)
285
287
94%
0.003 (0.001)
6 to 7
54 (50–58)
229
290
95%
0.001 (0.0007)
7 to 8
53 (49–57)
181
293
96%
0.002 (0.0009)
8 to 9
52 (47–56)
155
297
97%
0.002 (0.0012)
9 to 10
51 (47–55)
128
298
98%
0.001 (0.0007)
10 to 14
46 (41–51)
110
305
100%
 

Event-Free at 3 Years

Patient and tumor characteristics for the 377 patients that were event-free and alive at 3 years from diagnosis are further described in Table 2. Seventy-seven percent of these tumors were high-grade, and the most common histological subtypes were undifferentiated pleomorphic sarcoma (21%), leiomyosarcoma (21%), and myxofibrosarcoma (18%). Less frequent subtypes (n < 10) were grouped for analysis. Of the STS located in the extremities, 96% underwent limb-sparing surgery for the primary tumor. The median age at diagnosis was 64 years (mean 60; range 18–96) with slight male predominance (57%). Median tumor size was 6 cm (mean 7; range 1–28). Ninety-two percent (95% CI 88.9–94.6) and 83% (95% CI 77.6–87.1) of these patients were still event-free at 5 and 10 years from diagnosis, respectively. The median follow-up time was 7.7 years (mean 9.1; range 3–26).
Table 2
Overview of patients and tumor characteristics
Characteristic
n = 377
%
Median age at diagnosis in years (mean; range)
64 (60; 18–96)
 
 Male
214
57
 Female
163
43
Tumor depth (n, %)
  
 Superficial
175
47
 Deep
196
53
 Not available
6
 
Tumor site (n, %)
  
 Upper trunk
29
8
 Lower trunk
15
4
 Shoulder
18
5
 Upper arm
36
9
 Elbow
11
3
 Lower arm
30
8
 Hand
5
1
 Gluteal
23
6
 Groin
11
3
 Thigh
136
36
 Knee
11
3
 Lower leg
38
10
 Foot
14
4
Median tumor diameter in cm (mean; range)
6 (7; 1–28)
 
Tumor grade (n, %)
  
 1
24
7
 2
55
16
 3
71
20
 4
201
57
 Not available
26
 
Vascular invasion
  
 Yes
38
12
 No
273
88
 Not available
66
 
Necrosis
  
 Yes
167
52
 No
157
48
 Not available
53
 
Growth pattern
  
 Pushing
20
19
 Infiltrative
88
81
 Not available
269
 
Histologic subtype (n, %)
  
 Undifferentiated pleomorphic sarcoma
78
21
 Myxofibrosarcoma
68
18
 Liposarcoma
47
12
 Leiomyosarcoma
81
21
 Synovial sarcoma
19
5
 Malignant peripheral nerve sheath tumor
18
5
 Other typea
66
18
Surgical procedure (n, %)b
  
 Limb salvage
321
96
 Amputation
12
4
 Surgical margin (n, %)
  
 R0 wide
252
67
 R0 marginal
109
29
 R1
15
4
 R2
0
0
 Not available
1
 
Radiotherapy
  
 Yes
129
34
 No
248
66
Chemotherapy
  
 Yes
45
12
 No
332
88
aAlveolar soft part sarcoma, clear cell sarcoma, epithelioid sarcoma, low-grade fibromyxoid sarcoma, solitary fibrous tumor, fibrosarcoma, unclassified sarcoma and angiosarcoma
bNot applicable to the 44 patients with tumors located to the trunk wall
Late recurrence was diagnosed in 55 (15%) of the 377 patients who were free from disease and alive at 3 years from diagnosis, or 8% of the initial cohort of 677 patients. LR was recorded in 23 patients, DM in 21 patients, and both LR and DM in 11 patients.

Late Local Recurrence

Late LR was recorded in 34 of the 377 patients. The median time to late LR was 5 years (mean 5.8; range 3–13) from diagnosis. R0 marginal (HR 3.3; p = 0.001) or R1 surgical margin (HR 5.4; p = 0.003) and radiotherapy (HR 2.3; p = 0.015) revealed statistically significant correlations with late LR using univariable analysis. None of the 19 patients with synovial sarcoma developed late LR (Table 3). When multivariable analysis was performed, R1 (HR 5.0; p = 0.005) and R0 marginal (HR 2.6; p = 0.02) surgical margins were independently associated with late LR, while radiotherapy was not (Table 4). Age, sex, malignancy grade, histological subtype, tumor site, depth, chemotherapy, and the SING factors (size, vascular invasion, necrosis, and peripheral growth pattern) did not reveal any statistically significant correlation with late LR.
Table 3
Univariable Cox proportional hazard model analysis of prognostic factors for late local recurrences
 
Patients
Local recurrence
%
HR
95% CI
p value
p value b
Age (year)
       
 < 64
183
16
8.7
Reference
   
 ≥ 64
194
18
9.3
1.2
0.6–2.4
0.58
0.58
Sex
       
 Male
214
21
9.8
Reference
   
 Female
163
13
8.0
0.8
0.4–1.6
0.48
0.48
Depth
       
 Superficial
175
16
9.1
Reference
   
 Deep
196
18
9.2
0.8
0.4–1.7
0.63
0.63
 Not available
6
0
     
Location
       
 Lower extremity
233
24
10
Reference
   
 Upper extremity
100
6
6.0
0.6
0.2–1.4
0.25
 
 Trunk
44
4
9.1
0.9
0.3–2.5
0.82
0.48
Size (cm)
       
 < 5
144
10
6.9
Reference
   
 ≥ 5
229
22
9.6
1.3
0.6–2.8
0.46
0.45
 Not available (cm)
4
2
     
 < 8
244
16
6.6
Reference
   
 ≥ 8
129
16
12
1.9
0.9–3.7
0.08
0.08
Not available
4
2
     
Malignancy grade
       
 Low-grade
81
5
6.2
Reference
   
 High-grade
282
28
10
1.6
0.6–4.2
0.32
0.30
 Not available
14
1
     
Vascular invasion
       
 No
273
21
7.7
Reference
   
 Yes
38
4
11
1.4
0.5–4
0.55
0.57
 Not available
66
9
     
Necrosis
       
 No
157
13
8.3
Reference
   
 Yes
167
14
8.4
1.1
0.5–2.3
0.81
0.81
 Not available
53
7
     
Growth pattern
       
 Pushing
20
2
10
Reference
   
 Infiltrative
88
7
8.0
0.8
0.2–3.9
0.76
0.76
 Not available
269
25
     
Histology
       
 UPS
78
10
13
Reference
   
 Leiomyosarcoma
81
4
4.9
0.4
0.1–1.4
0.16
 
 Liposarcoma
47
3
6.4
0.5
0.1–1.9
0.31
 
 MPNST
18
3
17
1.0
0.3–4
0.90
 
 Myxofibrosarcoma
68
8
12
0.8
0.5–3.2
0.63
 
 Synovial sarcoma
19
0
0
–*
   
 Other
66
6
9.1
0.7
0.3–2.1
0.60
0.15
Surgical procedure a
       
 Local excision
321
30
9.3
Reference
   
 Amputation
12
0
0
   
Final surgical margin
       
 R0 wide
252
13
5.2
Reference
   
 R0 marginal
109
16
15
3.3
1.6–6.8
0.001
 
 R1
15
4
27
5.4
1.8–16.6
0.003
0.001
 Not available
1
1
     
Radiotherapy
       
 No
248
18
7.3
Reference
   
 Yes
129
16
12
2.3
1.2–4.6
0.015
0.017
Chemotherapy
       
 No
332
30
9.0
Reference
   
 Yes
45
4
8.9
1.4
0.5–4.0
0.55
0.56
UPS undifferentiated pleomorphic sarcoma; MPNST malignant peripheral nerve sheath tumor
aNot applicable to the 44 patients with tumors located to the trunk wall
bOverall likelihood ratio test
Table 4
Multivariable Cox proportional hazard model analysis of prognostic factors for late recurrence
 
Late local recurrence
Late metastasis
 
HR
95% CI
p value
p valuec
HR
95% CI
p value
p valuec
Size (cm)
        
 < 5
    
Reference
   
 ≥ 5
    
2.6
0.9–7.7
0.09
0.09
 Not available
        
Malignancy grade
        
 Low-grade
    
Referencea
   
 High-grade
    
8.3
1.1–61
0.04
0.04
 Not available
        
Vascular invasion
        
 No
    
Reference
   
 Yes
    
1.1
0.4–2.9
0.82
0.82
 Not available
        
Final surgical margin
        
 R0 wide
Reference
   
Referenceb
   
 R0 marginal
2.6
1.1–6.1
0.02
 
2.3
1–5.2
0.04
 
 R1
5.0
1.6–16
0.005
0.009
1.4
0.2–11
0.73
0.065
 Not available
        
Radiotherapy
        
 No
Reference
       
 Yes
1.6
0.7–3.4
0.27
0.27
    
aVascular invasion was left out when analyzing malignancy grade due to missing values violating the analysis
bTumor size was left out when analyzing R1 intralesional surgical margin due to missing values violating the analysis
cOverall likelihood ratio test
The LR were treated with local excision in 29 cases (85%) and amputation in 4 cases (12%). One patient with late LR was not surgically treated due to severe comorbidity.
The LR were identified by the patient in-between clinical visits in 17 cases, on clinical follow-up visits in 7 cases, and in 3 cases by MRI performed of the primary tumor site, due to unspecified local symptoms. Data were not available in 7 cases.
The 3- and 5-year OS from the date of late LR was 77% (95% CI 58–88) and 63% (95% CI 43–78), respectively, compared with 45% (95% CI 36–53) and 40% (95% CI 31–48) for those with an early LR (p = 0.01; Fig. 1b).

Late Metastasis

Late DM was recorded in 32 of the 377 patients. The median time to late DM was 6.2 years (mean 7.1; range 3–13) from diagnosis of the primary tumor. For patients with both late LR and DM, the DM were identified at a median of 31 months (mean 41; range 4–95) after the preceding late LR.
Univariable statistical analysis showed that late DM was associated with high malignancy grade (HR 4.6; p = 0.04), size ≥5 cm (HR 3; p = 0.003), and vascular invasion (HR 2.9; p = 0.01) (Table 5). A statistically significant correlation was also seen with R0 marginal margin (HR 2.2; p = 0.04) but not with R1 margin (HR 1.7; p = 0.48), resulting in a nonsignificant global significance test (p = 0.11). The multivariable analysis revealed that high malignancy grade (HR 8.3; p = 0.04) was independently correlated with risk of late DM. This also was observed for R0 marginal margin (HR 2.3; p = 0.04), but the global significance test was nonsignificant (p = 0.065; Table 4). We could not find any statistical correlations between late DM and age, sex, histological subtype, tumor size dichotomized at 8 cm, tumor site, depth, surgical procedure, tumor necrosis, peripheral growth pattern, radiotherapy, or chemotherapy.
Table 5
Univariable Cox proportional hazard model analysis of prognostic factors for late metastasis
 
Patients
Metastasis
%
HR
95% CI
p value
p valueb
Age (year)
       
 < 64
183
26
8.7
Reference
   
 ≥ 64
194
16
8.2
1.1
0.6–2.3
0.71
0.71
Sex
       
 Male
214
19
8.9
Reference
   
 Female
163
13
8.0
0.9
0.4–1.8
0.70
0.70
Depth
       
 Superficial
175
13
7.4
Reference
   
 Deep
196
19
9.7
1.0
0.5–2
0.90
0.90
 Not available
6
0
     
Location
       
 Lower extremity
233
21
9.0
Reference
   
 Upper extremity
100
7
7.0
0.8
0.4–2
0.69
 
 Trunk
44
4
9.1
1.0
0.3–2.9
0.99
0.92
Size (cm)
       
 < 5
144
5
3.5
Reference
   
 ≥ 5
229
25
11
3.0
1.2–7.9
0.03
0.01
 Not available (cm)
4
2
     
 < 8
244
17
7.0
Reference
   
 ≥ 8
129
13
10
1.4
0.7–2.8
0.40
0.41
 Not available
4
2
     
Malignancy grade
       
 Low-grade
81
2
2.5
Reference
   
 High-grade
282
29
11
4.6
1.1–19
0.04
0.009
 Not available
14
1
     
Vascular invasion
       
 No
273
20
7.3
Reference
   
 Yes
38
8
21
2.9
1.3–6.7
0.01
0.02
 Not available
66
4
     
Necrosis
       
 No
157
12
7.6
Reference
   
 Yes
167
16
9.6
1.4
0.7–3
0.35
0.35
 Not available
53
4
     
Growth pattern
       
 Pushing
20
2
10
Reference
   
 Infiltrative
88
3
3.4
0.4
0.1–2.2
0.27
0.29
 Not available
269
27
     
Histology
       
 UPS
78
9
12
Reference
   
 Leiomyosarcoma
81
7
8.6
1.0
0.4–2.7
0.97
 
 Liposarcoma
47
1
2.1
0.2
0–1.5
0.12
 
 MPNST
18
3
17
1.2
0.3–4.4
0.80
 
 Myxofibrosarcoma
68
3
4.4
0.6
0.2–2.2
0.43
 
 Synovial sarcoma
19
1
5.3
0.4
0.1–3.2
0.40
 
 Other
66
8
12
1.3
0.5–3.5
0.56
0.32
Surgical procedurea
       
 Local excision
321
27
8.4
Reference
   
 Amputation
12
1
8.3
0.7
0.1–5.5
0.77
0.76
Final surgical margin
       
 R0 Wide
252
16
6.3
Reference
   
 R0 Marginal
109
14
13
2.2
1.1–4.4
0.04
 
 R1
15
2
13
1.7
0.4–7.4
0.48
0.11
 Not available
1
0
     
Radiotherapy
       
 No
248
21
8.5
Reference
   
 Yes
129
11
8.5
1.4
0.7–2.9
0.37
0.38
Chemotherapy
       
 No
332
27
8.1
Reference
   
 Yes
45
5
11
2.5
0.9–6.6
0.07
0.10
UPS undifferentiated pleomorphic sarcoma; MPNST malignant peripheral nerve sheath tumor
aNot applicable to the 44 patients with tumors located to the trunk wall
bOverall likelihood ratio test
The 3- and 5-year OS from the date of late DM were 42% (95% CI 24–58) and 27% (95% CI 12–44), respectively, compared with 20% (95% CI 15–26) and 11% (95% CI 7–16) for early DM (p = 0.01; Fig. 1c).
The late DM were located in the lungs in 14 cases, multiple sites in 6 cases, and lymph nodes in 5 cases. The remaining 7 cases were DM to soft tissue or bone. Nineteen patients had surgery for DM.

Discussion

The clinical importance of established risk factors to provide prognostic information regarding late recurrences is unclear, and somewhat contradictory results have been provided in previous studies.1821 We have analyzed a population-based series of soft tissue sarcomas to evaluate if it is possible to identify patients with an increased risk of late recurrence.
Late recurrence in the literature are often defined as a recurrence diagnosed later than 5 years after the primary diagnosis and treatment.19,20,22 We have chosen 3 years, because we believe it better reflects the recurrence pattern of STS. After 3 years, the incidence of recurrences even out and the hazard rate stays consistent for the years following thereafter (Table 1; Fig. 1a). Moreover, guidelines recommend longer surveillance interval for high-grade tumors to twice a year after 2–3 years, at which time approximately 80% of recurrences have been identified.3,5,10,14,15,31
We found, as expected, that surgical margin correlated with risk of developing late LR. Using R0 wide margin as reference, both R0 marginal and R1 margins were factors that indicated increased risk for late LR. The observed univariable statistical correlation between radiotherapy and increased frequency of late LR, however, is interpreted as being caused by confounding factors, because patients who received radiotherapy, in general, were selected due to inadequate surgical margins and high-risk tumor characteristics.
Surgical margin also correlated with increased risk for late DM, although the global significance test was nonsignificant. An R0 marginal surgical margin correlated with increased risk for late DM, and there was a trend for a correlation of R1, although not statistically significant. The latter is probably explained by a type II error as a result of a small sample size. Tumor size ≥5 cm and vascular invasion had a statistically significant correlation with late DM in univariable analysis but could not be shown to be independent risk factors when performing multivariable analysis. The only risk factor for late DM that remained statistically significant in multivariable analysis was high malignancy grade.
It has been suggested that low-grade tumors may be prone to recur late, but this is not in line with the results in this study.5,32 Of 100 patients with low-grade tumor, LR occurred in 17 cases of which 5 were late. The primary tumor was excised with R0 wide surgical margin in 3 of these 17 cases. Eight of 100 patients with low-grade tumors developed DM, of whom 6 presented early and 2 presented late. None of these tumors were operated with R0 wide margin, suggesting that patients with low-grade STS treated with R0 wide margin run a low risk for both LR and DM.
Although treatment of recurrent sarcoma may be challenging, we found that the 3- and 5-year OS from diagnosis and treatment of a late LR were comparable to the 3- and 5-year OS for patients after primary diagnosis and treatment of STS.33,34 Moreover, outcome for patients treated for late recurrences, both LR and DM, was better than for patients treated for early recurrences.
In this study, approximately one-third of late DM were preceded by a late LR. It has been discussed whether the increased incidence of DM following LR is subsequent to the LR itself, but this is now more considered a manifestation of an aggressive tumor biology.7,21,35
Recurrence following a long period of remission after treatment constitutes a clinical problem in various malignancies.36 The causing mechanisms are poorly understood, but it is suggested that late recurrence involves multiple mechanisms of tumor dormancy, such as immunosurveillance, angiogenic dormancy, and cellular dormancy (G0–G1 arrest) by disrupted signaling pathways in the microenvironment.36,37 In this series, STS patients with late events, both LR and DM, had better post-recurrence survival compared with those with early recurrence (Fig. 1b, c) irrespective of tumor histotype. This suggests unknown biological differences between tumors in early and late STS recurrences.
In the literature, reports of surgical margins differ and various margin classification systems are used.38 It has been shown that a system that distinguishes marginal margin from wide margin provides more prognostic information than a dichotomous system that only reports negative versus positive margin.3941 It has been argued that a marginal margin behaves closer to a positive margin than a negative margin.39 We found that R0 marginal margin is correlated with increased frequency of late events compared R0 wide margin, both classified as negative margin.
Early detection of LR and DM may increase chances to offer effective treatment and improve the chance of long-term survival. Studies have shown that approximately one-half of LR are detected by the patient in-between clinical visits, which is in line with our findings.15,4244 In our series, late LR were identified by the patient in 17 of the 27 cases with available data. In a study by Nakamura et al., approximately one-half of all recurrences (either LR or DM) diagnosed later than 5 years from the initial treatment were detected at follow-up and the other half due to clinical symptoms.19 Hence, patient information and awareness of self-examination is an important strategy to improve surveillance as a complement to the routine follow-up.
We were not able to define any specific characteristics of patients or tumors that predict a high risk of late recurrence. Risk factors for late recurrence appear to be the same as for early (supplementary tables), but many risk factors predicting early recurrence did not predict late recurrence. Nonwide surgical margin was associated with increased risk for late recurrence, both LR and DM. We, therefore, emphasize the importance of regular and long-term surveillance for these patients. After treatment of a late LR, it is reasonable to schedule an adequate follow-up strategy, because about one-third of the patients were later diagnosed with DM. High-grade tumors, especially when excised with close margin, should be followed for a long period of time as the risk of late recurrence was not negligible, and the outcome after treatment in this series was good.
This study was performed using data collected prospectively to the national sarcoma quality register during a long period of time. The rarity of late events result in a limited number of cases. This reduces the possibilities to draw strong conclusions and identify clear patterns for risk factors predicting prognosis and outcome. Comparison of results also are made more complicated by international and historical differences in grading systems and resection margins for STS. However, this study is based on a population based series of STS, with long median follow-up and therefore may be considered to reveal a good reflection of incidence and outcome for patients with late recurrence.
In summary, the study confirms that late recurrences of soft tissue sarcoma are relatively rare. Nevertheless, late recurrences do occur and are often successfully treated. Approximately one-third of late DM were preceded by a late LR. Hence, patients should be followed frequently after treatment of a late LR. The better survival after late recurrence might be explained by differences in tumor biology, indicating that early events reflect a more aggressive tumor, even if representing the same histopathologic entity. This calls for an active surveillance strategy of all STS patients with high-grade tumors, because long-term survival indeed is possible to achieve even after a late recurrence.

Acknowledgment

This work was supported by the Maggie Stephens foundation, Erik and Angelica Sparres research foundation, Greta and Johan Kocks foundation, Skåne University Hospital Donation and Research Foundation, research grant from Region Skåne and through a regional agreement between Lund University and the Skåne County Council (ALF F 2014/413).

Disclosure

None.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

Die Chirurgie

Print-Titel

Das Abo mit mehr Tiefe

Mit der Zeitschrift Die Chirurgie erhalten Sie zusätzlich Online-Zugriff auf weitere 43 chirurgische Fachzeitschriften, CME-Fortbildungen, Webinare, Vorbereitungskursen zur Facharztprüfung und die digitale Enzyklopädie e.Medpedia.

Bis 30. April 2024 bestellen und im ersten Jahr nur 199 € zahlen!

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Anhänge

Supplementary Information

Below is the link to the electronic supplementary material.
Literatur
39.
Zurück zum Zitat Hasley I, Gao Y, Blevins AE, Miller BJ. The significance of a “close” margin in extremity sarcoma: a systematic review. Iowa Orthop J. 2018;38:123–30.PubMedPubMedCentral Hasley I, Gao Y, Blevins AE, Miller BJ. The significance of a “close” margin in extremity sarcoma: a systematic review. Iowa Orthop J. 2018;38:123–30.PubMedPubMedCentral
Metadaten
Titel
Late Local Recurrence and Metastasis in Soft Tissue Sarcoma of the Extremities and Trunk Wall: Better Outcome After Treatment of Late Events Compared with Early
verfasst von
Arvid von Konow, MD
Iman Ghanei, MD
Emelie Styring, MD, PhD
Fredrik Vult von Steyern, MD, PhD
Publikationsdatum
16.04.2021
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-09942-8

Weitere Artikel der Ausgabe 12/2021

Annals of Surgical Oncology 12/2021 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.